Literature DB >> 6626276

Nifedipine as a therapeutic modality for Raynaud's phenomenon.

E L Winston, K M Pariser, K B Miller, D N Salem, M A Creager.   

Abstract

Eight patients with Raynaud's phenomenon were entered into a double-blind crossover study of nifedipine versus placebo, with 7 patients undergoing finger plethysmography before and after sublingual nifedipine administration. While receiving nifedipine, all patients reported decreased frequency and severity of attacks, and 4 of 5 had digital ulcer healing. Total finger blood flow increased 5 of 6 patients after treatment with sublingual nifedipine. This preliminary study indicates that nifedipine may be a useful agent for treatment of digital vasospasm.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626276     DOI: 10.1002/art.1780261001

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  The current treatment of scleroderma.

Authors:  G F Oliver; R K Winkelmann
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

4.  Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

Authors:  M Rademaker; E D Cooke; N E Almond; J A Beacham; R E Smith; T G Mant; J D Kirby
Journal:  BMJ       Date:  1989-03-04

5.  A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon.

Authors:  M B Finch; S Copeland; A P Passmore; G D Johnston
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

6.  Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.

Authors:  S J Hawkins; C M Black; N D Hall; A McGregor; E F Ring; P J Maddison
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

7.  Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.

Authors:  T Gjørup; O J Hartling; H Kelbaek; S L Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Effects of verapamil on calcium-induced rigidity and on filterability of red blood cells from healthy volunteers and patients with progressive systemic sclerosis.

Authors:  S O Sowemimo-Coker; I B Kovacs; J D Kirby; P Turner
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

9.  A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.

Authors:  A Kahan; B Amor; C J Menkes
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

Review 10.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.